SCHEMBL2082563

SCHEMBL2082563

C=CC[C@](C(=O)O)(C(=O)OCc1ccccc1)[C@@H](C)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
TSHR P16473 1/20 0.41
CTSK P43235 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
SYK P43405 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPK1 P28482 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SLC15A1 P46059 1/20 0.37
CTSL P07711 2/20 0.37
CTSS P25774 2/20 0.37
CTSB P07858 1/20 0.37
LMNA P02545 1/20 0.36
PTPN1 P18031 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082566 1.00 ALDH1A1 (0.41) ALDH1A1TSHRCTSKSMN1; SMN2MAPT
SCHEMBL29220175 0.85 ALDH1A1 (0.46) ALDH1A1TSHRSMN1; SMN2MAPTHCAR2
SCHEMBL2083933 0.81 CTSL (0.42) SMN1; SMN2CTSLCTSB
SCHEMBL24627654 0.79 ALDH1A1 (0.47) ALDH1A1TSHRSMN1; SMN2HCAR2L3MBTL1
SCHEMBL14266053 0.77 CTSK (0.44) CTSKSMN1; SMN2SYKKMT2ACTSL
SCHEMBL5117346 0.77 CTSK (0.44) CTSKSMN1; SMN2SYKKMT2ACTSL
SCHEMBL29220153 0.76 ALDH1A1 (0.50) ALDH1A1TSHRSMN1; SMN2HCAR2L3MBTL1
SCHEMBL1273767 0.76 ALDH1A1 (0.50) ALDH1A1TSHRSMN1; SMN2HCAR2L3MBTL1
SCHEMBL24425865 0.75 ALDH1A1 (0.49) ALDH1A1TSHRHCAR2L3MBTL1MAPK1
SCHEMBL9326476 0.75 MAPT (0.43) CTSKMAPTSYKTDP1CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902218-B2 Inhibit production of A beta -peptide; neurological disorders, Alzheimer's disease; (S)-2-((S)-3-Acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)-4-phenylbutanamide BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 US disclosed
US-20080153868-A1 Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153868-A1 Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors BACE1, APP, BACE2 ALDH1A1 3415/4885TSHR 3868/4885CTSK 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.